SCHEMBL3112551

SCHEMBL3112551

CCNC(=O)c1ccc(-n2nnc(C(=O)NCC(=O)OC)c2CSC)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ XDH P47989 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ TSHR P16473 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ STAMBP O95630 1/20 0.36
▸ POLB P06746 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3112834 0.85 HPGD (0.43) L3MBTL1ALDH1A1CYP1A2CYP2C19HPGD
SCHEMBL3113746 0.85 RIPK1 (0.41) ALDH1A1CYP1A2CYP2C19HPGDCYP2C9
SCHEMBL3114145 0.85 CYP1A2 (0.42) ALDH1A1CYP1A2CYP2C19HPGDCYP2C9
Hydrochloric Acid SCHEMBL3117772 0.84 RAB9A (0.41) L3MBTL1ALDH1A1CYP1A2CYP2C19HPGD
SCHEMBL5246149 0.84 RAB9A (0.43) L3MBTL1ALDH1A1CYP1A2CYP2C19HPGD
SCHEMBL5244694 0.84 HPGD (0.48) ALDH1A1CYP1A2CYP2C19HPGDCYP2C9
SCHEMBL5246092 0.83 EPHX2 (0.53) L3MBTL1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL5246999 0.82 HDAC1 (0.46) ALDH1A1CYP1A2CYP2C19RECQLCYP2D6
SCHEMBL5246648 0.82 NAMPT (0.39) L3MBTL1ALDH1A1CYP1A2CYP2C19HPGD
SCHEMBL3114784 0.82 RIPK1 (0.39) ALDH1A1CYP1A2CYP2C19HPGDCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 — — US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 — — US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 XDH 1591/4885L3MBTL1 1781/4885ALDH1A1 3580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback